Essential medicines in Hungary

Prezentace na téma: "Essential medicines in Hungary "— Transkript prezentace:

1 ESSENTIAL MEDICINES IN HUNGARY Arete-Zoe, LLC Date: July 22, 2017 Data lock point: April 28, 2017 https://www.aretezoe.com/

2 "We have essentially been avoiding this elephant in the room for the past twenty years, never daring to state what we know: namely that the use of public healthcare services does not reflect the needs of society, but rather the interests of the institutional system." Dr. Zoltán Ónodi-Szűcs, Hungarian Secretary of State for Health (Haynes, 2017) https://www.aretezoe.com/

3 System organ classWHO EML WHO EML Available WHO EML Unavailable WHO EML Unavailable % NL EML Both EM Lists (overlap) A – Alimentary tract and metabolic diseases3426824%3813 B – Blood and blood-forming organs3027310%52 C – Cardiovascular system2520520%8113 D – Dermatologicals21111048%143 G - Genito-urinary system, sex hormones1911842%324 H – Hormones, excl. sex hormones and insulins 11 00%63 J – Systemic anti-infectives119833630%2919 L – Anti-neoplastic agents, immunomodulants4539613%177 M – Musculoskeletal system64233%181 N – Nervous system373525%6211 P – Anti-parasitics, insecticides, repellents3672981%00 R – Respiratory system107330%244 S – Sensory organs137646%182 V - Various2112943%21 TOTAL42730112130%34683 https://www.aretezoe.com/ FIG. 1 - Summary (table): Availability of essential medicines by organ class

4 https://www.aretezoe.com/ FIG. 2 – Summary (graph): Essential medicines lists by organ class WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

5 https://www.aretezoe.com/ FIG. 3 – Summary (graph): Availability of essential medicines lists by organ class

6 ALIMENTARY TRACT AND METABOLISM (A) https://www.aretezoe.com/

7 FIG. 4 – Summary (graph): Availability of registered products (A) – WHO EM List WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

8 https://www.aretezoe.com/ FIG. 5 – Summary (graph): Availability of registered products (A) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

9 https://www.aretezoe.com/ FIG. 6 – Summary (graph): Availability of registered products (A) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

10 https://www.aretezoe.com/ FIG 7 – Stomatologicals (A01) and Acid related disorders (A02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

11 https://www.aretezoe.com/ FIG. 8 – Drugs for functional GIT disorders (A03), antiemetics and antinauseants (A04) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

12 https://www.aretezoe.com/ FIG. 9 – Bile and liver therapy (A05), drugs for constipation (A06), anti-diarrheals (A07) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

13 https://www.aretezoe.com/ FIG. 10 – Anti-obesity drugs (A08) and digestives incl. enzymes (A09) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

14 https://www.aretezoe.com/ FIG. 11 – Drugs used in diabetes (A10) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

15 https://www.aretezoe.com/ FIG. 12 - Vitamins (A11) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

16 https://www.aretezoe.com/ FIG. 13 - Mineral supplements (A12), other alimentary tract & metabolism drugs (A16) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

17 Unavailable WHO EML ATC CodeActive ingredient A04AD01hyoscine hydrobromide A06AA02docusate sodium A07AA6paromomycin A07EA02hydrocortisone A11CC01 ergocalciferol A11HA01 nicotinamide A11HA04 riboflavin A12CD01 sodium fluoride

18 BLOOD AND BLOOD- FORMING ORGANS (B) https://www.aretezoe.com/

19 FIG. 14 – Summary (graph): Availability of registered products (B) – WHO EM List and National EM List combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

20 https://www.aretezoe.com/ FIG 15 - Anti-thrombotic agents (B01) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

21 https://www.aretezoe.com/ FIG 16 – Anti-hemorrhagics (B02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

22 https://www.aretezoe.com/ FIG 17 – Anti-anemic preparations (B03) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

23 https://www.aretezoe.com/ FIG 18 – Blood substitutes and perfusion solutions (B05) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

24 Unavailable WHO EML ATC CodeActive ingredient B05AX01red blood cells B05AX03fresh frozen plasma B05XA05magnesium sulfate

25 CARDIOVASCULAR SYSTEM (C) https://www.aretezoe.com/

26 FIG. 20A – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

27 https://www.aretezoe.com/ FIG. 20B – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

28 https://www.aretezoe.com/ FIG 19 – Summary (graph): Availability of registered products (C) – WHO EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

29 https://www.aretezoe.com/ FIG. 20C – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

30 https://www.aretezoe.com/ FIG. 20D – Summary (graph): Availability of registered products (C) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

31 https://www.aretezoe.com/ FIG. 21A – Summary (graph): Availability of registered products (C) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

32 https://www.aretezoe.com/ FIG. 21B – Summary (graph): Availability of registered products (C) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

33 https://www.aretezoe.com/ FIG. 21C – Summary (graph): Availability of registered products (C) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

34 https://www.aretezoe.com/ FIG. 22 - Cardiac therapy (C01) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

35 https://www.aretezoe.com/ FIG. 23 - Antihypertensives (C02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

36 https://www.aretezoe.com/ FIG. 24 – Diuretics (C03) and peripheral vasodilatators (C04) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

37 https://www.aretezoe.com/ FIG. 25 – Vasoprotectives (C05) and beta-blocking agents (C07) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

38 https://www.aretezoe.com/ FIG. 26 - Calcium-channel blockers (C08) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

39 https://www.aretezoe.com/ FIG. 27 - Renin-angiotensin system: ACE inhibitors (C09A) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

40 https://www.aretezoe.com/ FIG. 28 - Renin-angiotensin system: ACE inhibitors in combinations (C09B) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

41 FIG. 29 - Renin-angiotensin system: Angiotensin II antagonists (C09C) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

42 FIG. 30 - Renin-angiotensin system: Angiotensin II antagonists in combinations (C09D) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

43 FIG. 31 - Lipid modifying agents (C10) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

44 Unavailable WHO EML ATC CodeActive ingredient C01CA26ephedrine C01DA08isosorbide dinitrate C02DB02hydrazaline C02DD01nitroprusside C03DB01amiloride

45 DERMATOLOGICALS (D) https://www.aretezoe.com/

46 FIG. 32 – Summary (graph): Availability of registered products (D) – WHO EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

47 FIG. 33 – Summary (graph): Availability of registered products (D) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

48 FIG. 34 – Summary (graph): Availability of registered products (D) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

49 FIG. 35 - Antifungals for dermatological use (D01) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

50 FIG. 36 - Emollients and protectives (D02), antipsoriatics (D05) and antibiotics and chemotherapeutics for dermatological use (D06) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

51 FIG. 37 – Corticosteroids for dermatological use (D07) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

52 FIG. 38 – Antiseptics and disinfectants (D08) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

53 FIG. 39 – Anti-acne preparations (D10) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

54 Unavailable WHO EML ATC CodeActive ingredient D01AA01nystatin D01AC02miconazole D01AE12salicylic acid D01AE13selenium sulfide D01BA01griseofulvin D08AC02chlorhexidine D08AE05chloroxylenol D08AX05isopropanol D08AX06potassium permanganate D08AX08ethanol

55 GENITO-URINARY SYSTEM AND SEX HORMONES (G) https://www.aretezoe.com/

56 FIG. 40 – Summary (graph): Availability of registered products (G) – WHO EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

57 FIG. 41 – Summary (graph): Availability of registered products (G) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

58 FIG. 42 – Summary (graph): Availability of registered products (G) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

59 FIG. 43 - Antiinfectives and antiseptics (G01), other gynecologicals (G02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

60 FIG. 44 – Hormonal contraceptives for systemic use: Progestogens and estrogens, fixed combinations (G03AA) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

61 FIG. 45 – Hormonal contraceptives for systemic use: Progestogens and estrogens, sequential preparations (G03AB) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

62 FIG. 46 –Progestogens (G03AC) and emergency contraceptives (G03AD) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

63 FIG. 47 – Androgens (G03B), estrogens (G03C), progestogens (G03D) androgens and female hormones comb. (G03E), and progestogens and estrogens comb. (G03F) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

64 FIG. 48 – Gonadotropins and other ovulation stimulants (G03G), antiandrogens (G03H) and other sex hormones and modulators of the genital system (G03X) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

65 FIG. 49 – Urologicals (G04) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

66 Unavailable WHO EML ATC CodeActive ingredient G02AB03ergometrine G02BA02plastic IUD with copper G02BA03plastic IUD with progesteron G03AA05norethisterone and ethinylestradiol G03AA08medroxyprogesterone and estrogen G03AC01norethisterone G03AC03levonorgestrel G03AC08etonorgestrel

67 HORMONES FOR SYSTEMIC USE, EXCL. SEX HORMONES AND INSULINS (H) https://www.aretezoe.com/

68 FIG. 50 – Summary (graph): Availability of registered products (H) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

69 FIG. 51 – Pituitary and hypothalamic hormones and analogues (H01), corticosteroids for systemic use (H02) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

70 FIG. 52 – Thyroid therapy (H03), pancreatic hormones (H04), calcium homeostasis (H05) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

71 ANTIINFECTIVES FOR SYSTEMIC USE (J) https://www.aretezoe.com/

72 FIG. 53 – Summary (graph): Availability of registered products (J) – WHO EML (values <4 included in table 56C) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

73 FIG. 54 – Summary (graph): Availability of registered products (J) – National EML WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

74 FIG. 55A – Summary (graph): Availability of registered products (J) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

75 FIG. 55B – Summary (graph): Availability of registered products (J) – WHO EML and National EML combined WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

76 FIG. 55C – Summary (table): Availability of registered products (J) – WHO EML and National EML combined (1-3 registrations) lymecyclineTyphoid vaccines ampicillinpapillomavirus (human types 16, 18) sulfamethoxazole + trimethoprimbenzylpenicillin gentamicinprocain benzylpenicilin amikacincefazolin metronidazoleerythromycin saquinavir (SQV)nitrofurantoin lamivudine + zidovudine (ZDV or AZT)isoniazid meningococcal vaccinesethambutol pneumococcus, purified polysaccharides Agbedaquiline Poliomyelitis vaccinedelamanid Rota virus diarrhea vaccinessimeprevir Varicella zoster vaccinesefavirenz + emtricitabine + tenofovir fosfomycin sofosbuvir ketoconazole dasabuvir p-aminosalicylic acidledipasvir + sofosbuvir rifampicinCholera vaccines pyrazinamidanti-D immunoglobulin rifampicin and isoniazidtetanus immunoglobulin abacavir (ABC)tetanus toxoid daclatasvirhemophilus influenzae B, purified antigen conjugated tuberculosis, live attenuated encephalitis, Japanese, inactivated, whole virus Yellow fever vaccines

77 FIG. 55D – Summary (table): Availability of registered products (J) – WHO EML and National EML combined (Not available) chloramphenicolclofazimine benzathin benzylpenicilindapsone cloxacillinlopinavir + ritonavir (LPV/r) cefalexinzidovudine (ZDV or AZT) trimethoprimentecavir sulfadiazinelamivudine + nevirapine + zidovudin streptomycinlamivudine + nevirapine + stavudine kanamycinombitasvir + paritaprevir + ritonavir spectinomycindiphtheria antitoxin flucytosinesnake venom antiserum cycloserinerabies immunoglobulin rifabutindiphtheria toxoid rifapentinepertussis vaccine capreomycinmeasles vaccine, live attenuated protionamidemumps vaccine, live attenuated ethionamideRubella vaccines terizidone ethambutol and isoniazid rifampicin, pyrazinamide and isoniazid rifampicin, pyrazinamide, ethambutol and isoniazid

78 FIG. 56 - Antibacterials (J01): Tetracyclines (J01A) amphenicols (J01B) WHO List of Essential Medicines National List of Essential Medicines Drug listed on both Lists

79 FIG. 57 - Antibacterials (J01): Beta-lactams – penicillins (J01C)

80 FIG. 58 - Antibacterials (J01): Beta-lactams – non-penicilline (J01D)

81 FIG. 59 - Antibacterials (J01): Sulphonamides and trimethoprim (J01E) and macrolides, linkosamides and streptogramins (J01F)

82 FIG. 60 - Antibacterials (J01): Aminoglycosides (J01G)

83 FIG. 61 - Antibacterials (J01): Quinolones (J01M)

84 FIG. 62 - Antibacterials (J01): Other antibacterials (J01X)

85 FIG. 63 – Antimycotics for systemic use (J02)

86 FIG. 64A – Antimycobacterials (J04): Tuberculosis (J04A)

87 FIG. 64B – Antimycobacterials (J04) Tuberculosis (J04A) and leprosy (J04B)

88 FIG. 65 – Antivirals for systemic use (J05): Nucleosides and nucleotides excl. reverse transcriptase inhibitors (J05AB) and Protease inhibitors (J05AE)

89 FIG. 66 – Antivirals for systemic use (J05): Nucleoside and nucleotide reverse transcriptase inhibitors (J05AF), Non-nucleoside reverse transcriptase inhibitors (J05G) and Neuraminidase inhibitors (J05AH)

90 FIG. 67 – Antivirals for systemic use (J05): Antivirals for treatment of HIV infections, combinations (J05AR) and Other antivirals (J05AX)

91 FIG. 68 – Immune sera and immunoglobulins (J06)

92 FIG. 69A – Vaccines (J07): Bacterial vaccines (J07A)

93 FIG. 69B – Vaccines (J07): Bacterial vaccines (J07A)

94 FIG. 70A – Vaccines (J07): Viral vaccines (J07B)

95 FIG. 70B– Vaccines (J07): Viral vaccines (J07B)

96 FIG. 70C– Vaccines (J07): Viral vaccines (J07B)

97 FIG. 71 – Vaccines (J07): Bacterial and viral vaccines combined (J07C)

98 Unavailable WHO EML ATC CodeActive ingredient Antibacterials J01BA01chloramphenicol J01CE08benzathin benzylpenicilin J01CF02cloxacillin J01DB01cefalexin J01EA01trimethoprim J01EC02sulfadiazine J01GA01streptomycin J01GB04kanamycin J01XX04spectinomycin Antimycotics J02AX01flucytosine

99 Unavailable WHO EML Antimycobacterials J04AB01cycloserine J04AB04rifabutin J04AB05rifapentine J04AB30capreomycin J04AD01protionamide J04AD03ethionamide J04AK03terizidone J04AM03ethambutol and isoniazid J04AM05rifampicin, pyrazinamide and isoniazid J04AM06rifampicin, pyrazinamide, ethambutol and isoniazid J04BA01clofazimine J04BA02dapsone

100 Unavailable WHO EML Antivirals J05AE30lopinavir + ritonavir (LPV/r) J05AF01zidovudine (ZDV or AZT) J05AF10entecavir J05AR05lamivudine + nevirapine + zidovudin J05AR07lamivudine + nevirapine + stavudine J05AX66ombitasvir + paritaprevir + ritonavir Immune sera and immuoglobulins J06AA01diphtheria antitoxin J06AA03snake venom antiserum J06BB05rabies immunoglobulin

101 Unavailable WHO EML ATC CodeActive ingredient Vaccines J07AF01diphtheria toxoid J07AJ01pertussis vaccine J07BD01measles vaccine, live attenuated J07BE01mumps vaccine, live attenuated J07BJRubella vaccines

102 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS (L) https://www.aretezoe.com/

103 FIG. 72A – Summary (graph): Availability of registered products (L) – WHO EML

104 FIG. 72B – Summary (graph): Availability of registered products (L) – WHO EML

105 FIG. 73 – Summary (graph): Availability of registered products (L) – National EML

106 FIG. 74A – Summary (graph): Availability of registered products (L) – WHO EML and National EML combined

107 FIG. 74B – Summary (graph): Availability of registered products (L) – WHO EML and National EML combined

108 FIG. 74C – Summary (graph): Availability of registered products (L) – WHO EML and National EML combined

109 FIG. 75 - Antineoplastic agents (L01): Alkylating agents (L01A)

110 FIG. 76 - Antineoplastic agents (L01): Antimetabolites (L01B)

111 FIG. 77 - Antineoplastic agents (L01): Plant alkaloids and other natural products (L01C)

112 FIG. 78 - Antineoplastic agents (L01): Cytotoxic antibiotics & related substances (L01D)

113 FIG. 79 - Antineoplastic agents (L01): Other antineoplastic agents (L01X)

114 FIG. 80 – Endocrine therapy (L02)

115 FIG. 81 – Immunostimulants (L03)

116 FIG. 82 - Immunosuppressants (L04)

117 Unavailable WHO EML ATC CodeActive ingredient L01AA02chlorambucil L01BB03tioguanine L01DA01dactinomycin L01XB01procarbazine L01XX09miltefosine L01XX14tretinoin

118 MUSCULO-SKELETAL SYSTEM (M) https://www.aretezoe.com/

119 FIG. 83 – Summary (graph): Availability of registered products (M) – WHO EML

120 FIG. 84 – Summary (graph): Availability of registered products (M) – National EML

121 FIG. 85 – Summary (graph): Availability of registered products (M) – WHO EML and National EML combined

122 FIG. 86 – Musculoskeletal system (M): Anti-inflammatory and anti-rheumatic products (M01)

123 FIG 87 – Musculoskeletal system (M): Topical products for joint and muscular pain (M02), muscle relaxants (M03)

124 FIG. 88 – Musculoskeletal system (M): Anti-gout preparations (M04), drugs for the treatment of bone diseases (M05)

125 Unavailable WHO EML ATC CodeActive ingredient M01CC01penicillamine M03AB01suxamethonium

126 NERVOUS SYSTEM (N) https://www.aretezoe.com/

127 FIG. 89A – Summary (graph): Availability of registered products (N) – WHO EML

128 FIG. 89B – Summary (graph): Availability of registered products (N) – WHO EML

129 FIG. 90A – Summary (graph): Availability of registered products (N) – National EML

130 FIG. 90B – Summary (graph): Availability of registered products (N) – National EML

131 FIG. 90C – Summary (graph): Availability of registered products (N) – National EML

132 FIG. 91A – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

133 FIG. 91B – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

134 FIG. 91C – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

135 FIG. 91D – Summary (graph): Availability of registered products (N) – WHO EML and National EML combined

136 FIG. 92 – Anesthetics (N01): General anesthetics (N01A)

137 FIG. 93 – Anesthetics (N01): Local anesthetics (N01B)

138 FIG. 94 – Analgesics (N02): Opioids (N02A)

139 FIG. 95 – Analgesics (N02): Other analgesics and antipyretics (N02B) and antimigraine products (N02C)

140 FIG. 96 – Antiepileptics (N03)

141 FIG. 97 – Anti-Parkinson drugs (N04)

142 FIG. 98 – Psycholeptics (N05): Antipsychotics (N05A)

143 FIG. 99 – Psycholeptics (N05): Anxiolytics (N05B)

144 FIG. 100 – Psycholeptics (N05): Hyponotics and sedatives (N05C)

145 FIG. 101 – Psychoanaleptics (N06): Antidepressants (N06A)

146 FIG. 102 – Psychoanaleptics (N06): Psychostimulants, agents used for ADHD and nootropics (N06B) and anti-dementia drugs (N06D)

147 FIG. 103 – Other nervous system drugs (N07): Parasympathomimetics (N07A), drugs used in addictive disorders (N07B), anti-vertigo preparations (N07C) and other (N07X)

148 Unavailable WHO EML ATC CodeActive ingredient N01AB01halotane N03AD01ethosuximide

149 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS (P) https://www.aretezoe.com/

150 FIG. 104 – Summary (graph): Availability of registered products (P) – WHO EM List and National EM List combined

151 FIG. 105 – Antiparasitics, insecticides and repellents (P): Antiprotozoals (P01), anthelmintics (P02) and ectoparasiticides (P03)

152 FIG. 106 – Antiparasitics, insecticides and repellents (P) – WHO EML unavailable ATC CodeActive ingredient P01AC01diloxanide P01BA02hydroxychloroquine P01BA03primaquine P01BA06amodiaquine P01BB01proguanil P01BC01quinine P01BD01pyrimethamine P01BD51pyrimethamine, comb. P01BE02artemether P01BE03artesunate P01BF01artemether and lumefantrine P01BF02artesunate and mefloquine P01BF03artesunate and amodiaquine P01CA02benznidazole P01CB01meglumine antimoniate ATC CodeActive ingredient P01CB02sodium stibogluconate P01CC01nifurtimox P01CD01melarsoprol P01CX01pentamidine isethionate P01CX02suramin sodium P01CX03eflornithine P02BA01praziquantel P02BA02oxamniquine P02BX04triclabendazole P02CB02diethylcarbamazine P02CC01pyrantel P02CF01ivermectin P02DA01niclosamide P03AX01benzyl benzoate

153 RESPIRATORY SYSTEM (R) https://www.aretezoe.com/

154 FIG. 107 – Summary (graph): Availability of registered products (R) – WHO EML and National EML combined

155 FIG. 108 – Summary (graph): Availability of registered products (R) – WHO EML and National EML combined

156 FIG. 109 – Respiratory system (R): Nasal preparations (R01)

157 FIG. 110 – Respiratory system (R): Throat preparations (R02) and drugs for obstructive airway diseases (R03)

158 FIG. 111 – Respiratory system (R): Cough and cold preparations (R05)

159 FIG. 112 – Respiratory system (R): antihistamines for systemic use (R06) and other respiratory system products (R07)

160 Unavailable WHO EML ATC CodeActive ingredient R03BA01beclometasone R05DA04codeine R06AE03cyclizine

161 SENSORY ORGANS (S) https://www.aretezoe.com/

162 FIG. 113 – Summary (graph): Availability of registered products (S) – WHO EML and National EML combined

163 FIG. 114 – Ophthalmologicals (S01): Antiinfectives (S01A)

164 FIG. 115 – Ophthalmologicals (S01): Antiinflammatory agents (S01B), Antiinflammatory angents and antiinfectives in combination (S01C), antiglaucoma preparations and miotics (S01E)

165 FIG. 116 – Ophthalmologicals (S01): Mydriatics and cycloplegics (S01F), decongestants and antiallergics (S01G), local anesthetics (S01H), and diagnostic agents (S01J)

166 Unavailable WHO EML ATC CodeActive ingredient S01AA09tetracycline S01AA11gentamicin S01BA04prednisolone S01EA01epinephrine S01FA01atropine S01HA03tetracaine

167 VARIOUS (V) https://www.aretezoe.com/

168 FIG. 117 – Summary (graph): Availability of registered products (V) – WHO EM List and National EM List combined

169 FIG. 118 – Various (V): All other therapeutic products (V03)

170 FIG. 119 – Various (V): Diagnostic agents (V04), all other non-therapeutic products (V07) and contrast media (V08)

171 Unavailable WHO EML ATC CodeActive ingredient V03AB03edetates V03AB06thiosulfate V03AB08sodium nitrite V03AB09dimercaprol V03AB31potassium ferric hexacyanoferrate (II) 2H2O (Prussian blue) V03AB34fomepizole V04CF01tuberculin, purified protein derivative (PPD) - BCG V07AVTechnical disinfectants V08AC02iotroxic acid

172 ARETE-ZOE, as a consultancy, provides solutions to complex problems in the high stakes and high consequence environment of Global Pharmaceuticals, including clinical research, healthcare informatics, and public health. We blend established, Pharma sector methodologies, innovation, and adaptations/transfers from other sectors to identify and resolve consequential practices that pose risk and often result in avoidable patient casualty. However, we are specifically, not a patient advocacy group but believe in optimizing organizational effectiveness and that smart business is agile, competitive and profitable, while intrinsically safe, secure, and resilient. We work within a global context because transnational interests influence national circumstances and choices at point of prescription. ARETE-ZOE, provides full spectrum organizational and operational risk management consultancy. Our published materials provide a glimpse of some aspects of our services to demonstrate both knowledge and ongoing participation within the Pharmaceutical Industry. Our analysis and consultancy includes all channels of misuse, diversion, counterfeiting and illicit exploitation of pharmaceuticals, medical devices, and precursor chemicals. Our advisement is to manufactures, jurisdictional entities, insurers, legislators, litigators, patients, and health care providers. ​ This scope also frequently segues into the nexus of crime and terrorism as significant influencers that undermine sector integrity differentiated from other criminal activity. Obviously, vulnerability assessment, information collection management and intelligence production supporting decision-making for risk reduction and interventions are routinely within the scope of our services as well as design and implementation of operational control measures. https://www.aretezoe.com/